Marketing: Page 77
-
Largest US benefits manager warns PCSK9 meds will 'wreak havoc' on payers
Express Scripts isn't mincing words about the price of new cholesterol meds like Sanofi/Regeneron's Praluent.
By Nicole Gray • July 30, 2015 -
Deep Dive
World Hepatitis Day: The transformation and enduring struggles of HCV treatment
After many years at the forefront of hepatitis C advocacy, Alan Franciscus, founder and executive director of the Hepatitis C Support Project, discusses the ups and downs of the evolving HCV treatment landscape.
By Nicole Gray • July 27, 2015 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
AbbVie reports disappointing Q2 sales, better-than-expected profits
It appears that biosimilars have yet to take a big chunk out of Humira sales.
By Nicole Gray • July 27, 2015 -
BMS and Exelixis make headway against Novartis in kidney cancer
But the Swiss pharma giant is still defending its cancer med Afinitor.
By Nicole Gray • July 23, 2015 -
The FDA wants to figure out DTC ad claims' effect on consumers
The FDA wants to know whether or not DTC drug ads actually change viewers' perceptions about medications.
By Nicole Gray • July 23, 2015 -
Tekmira to become Arbutus, shift focus to hep B
After Tekmira's merger with OnCore in March, the combined entity now boasts that largest hepatitis B (HBV) pipeline in the industry.
By Nicole Gray • July 21, 2015 -
WHO prequalifies Novartis' Coartem for malaria
The newest formulation of Coartem is the first and only high strength ACT antimalarial treatment available for large-scale public use.
By Nicole Gray • July 20, 2015 -
Deep Dive
Innovation vs. access: The big drug battle in Trans-Pacific Partnership negotiations
The generics industry worries over the intellectual property provisions of the complex trade agreement.
By Nicole Gray • July 17, 2015 -
ASCO scorecard upgrades rating for Lilly's Alimta
Alimta (pemetrexed) fell short on an initial scorecard, but its score improved when ratings were focused on a more specific form of lung cancer.
By Nicole Gray • July 16, 2015 -
Allergan faces lost sales as Namenda generics hit market
The drug giant is anticipating a $200 million loss in forecasted sales.
By Nicole Gray • July 16, 2015 -
NHS Scotland approves funding for five new drugs
Patients in Scotland now have access to newly covered drugs for thyroid cancer, pulmonary arterial hypertension, Crohn's disaease and other conditions -- but Lyparza, used to treat ovarian cancer, was rejected for funding.
By Nicole Gray • July 15, 2015 -
Study: Off-label use of antipsychotics growing in teens/young adults
A study published in JAMA Psychiatry reveals that 4.63 million antipsychotic prescriptions for written for teens and young adults in 2010.
By Nicole Gray • July 12, 2015 -
What Glaxo's strategy guru thinks the future holds for HIV markets
David Redfern said that eventually the only improvement left to make in treating HIV will be finding a permanent cure.
By Nicole Gray • July 10, 2015 -
Senior congressman joins chorus calling for heroin antidote price cut
Representative Elijah Cummings wrote to Governor Larry Hogan (R) to request that he cut a deal with Amphastar, which manufactures naloxone.
By Nicole Gray • July 9, 2015 -
Pharma's newest adversaries on CME funding are... Hotel workers?
A 270,000-person strong hotel worker's union is fighting to end what it calls "out-of-control" CME payments by the pharma industry.
By Nicole Gray • July 7, 2015 -
Pharma flings accusations, dire predictions in wake of Greek financial crisis
Some say that a 'Grexit' would severely impact access to medications and their prices, while others are accusing pharma of twisting a crisis to shield its bottom line.
By Nicole Gray • July 7, 2015 -
Big deal for biosims? Major French hospital group opts for Hospira's Remicade copy
Assistance Publique-Hôspitaux de Paris (AP-HP) is buying an infliximab biosimilar from the firm, which was acquired by Pfizer earlier this year, to treat its patients.
By Nicole Gray • July 6, 2015 -
Drug makers warn EU over troubled Greece: Medicine supply 'may be in jeopardy'
The industry is warning that the Greek drug-supply chain may be severely disrupted if Greece leaves the Euro zone.
By Nicole Gray • July 2, 2015 -
New study: Glaxo flu vax linked to increased narcolepsy risk
That's according to a study by Stanford researchers.
By Nicole Gray • July 2, 2015 -
Novo to halt Tresiba sales in Germany over pricing conflict
It's particularly striking given the size of the German market.
By Nicole Gray • July 2, 2015 -
Deep Dive
'Innovation' is everywhere in biopharma—but what does that actually mean?
Innovation has many definitions. But it can’t exist without collaborative partnerships.
By Nicole Gray • July 2, 2015 -
Sanofi/MannKind might be facing a major flop with Afrezza inhaled insulin
Executives from the companies have been urging patience and promising better results down the line. But so far, the numbers are pretty bleak.
By Nicole Gray • July 1, 2015 -
How Novartis' CEO wants to tackle an ever-aging world
Joe Jimenez spoke to McKinsey about his company's focus on serving the needs of an aging population.
By Nicole Gray • June 26, 2015 -
Bristol-Myers calls it quits on any new virology R&D programs
But the company's ongoing programs in virology will remain in place.
By Nicole Gray • June 26, 2015 -
Report: It pays big to focus on diabetes drugs
According to a report from GlobalData, the diabetes medications market grew 5.1% in 2014.
By Nicole Gray • June 25, 2015
Previous
